ORCHID project aims to slash development time of tuberculosis drugs
A collaborative project led by a scientist from UK pharma major GSK (LSE: GSK) has identified new compounds for the fight against TB.
The ORCHID (Open Collaborative Model for Tuberculosis Lead Optimisation), led by David Barros of GSK, has begun a four-year project to develop new drugs to fight drug-resistant TB and bring them to the marketplace in an efficient way. The ORCHID project is co-funded by the European Union.
Dr Barros said: “When ORCHID started, the last anti-tubercular drug (Rifampin) to be approved was back in the sixties. Efforts to discover new drugs for TB have been very fragmented and academic institutions have been conducting independent research with little or no links to the pharmaceutical industry.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze